Merck plans to spend $1 billion on constructing a new factory in Delaware to ensure a steady domestic supply of its blockbuster drug. This investment aims to enhance U.S. manufacturing capabilities and secure the production of Keytruda, one of Merck’s most successful medications. The project signifies Merck’s commitment to bolstering its domestic infrastructure and meeting the growing demand for its pharmaceutical products. The new biologics center of excellence in Wilmington, Delaware, is expected to play a crucial role in expanding Merck’s production capacity and reinforcing its position in the global market.
— new from WSJ